Pfizer (NYSE:PFE - Get Free Report) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided EPS guidance of 2.900-3.100 for the period, compared to the consensus EPS estimate of 3.005. The company issued revenue guidance of $61.0 billion-$64.0 billion, compared to the consensus revenue estimate of $62.4 billion.
Wall Street Analysts Forecast Growth
PFE has been the subject of a number of analyst reports. Berenberg Bank reduced their price objective on Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research report on Thursday, May 29th. Leerink Partners reduced their price objective on Pfizer from $28.00 to $26.00 and set a "market perform" rating for the company in a research report on Wednesday, April 30th. Wolfe Research boosted their price target on Pfizer from $22.00 to $23.00 and gave the stock an "underperform" rating in a research report on Wednesday, April 30th. Cantor Fitzgerald assumed coverage on Pfizer in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price target for the company. Finally, Citigroup boosted their price target on Pfizer from $23.00 to $25.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, six have issued a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $28.28.
View Our Latest Report on PFE
Pfizer Stock Up 5.3%
NYSE:PFE traded up $1.26 during trading hours on Tuesday, hitting $24.79. 78,966,836 shares of the company's stock traded hands, compared to its average volume of 45,672,621. The firm has a market cap of $140.91 billion, a P/E ratio of 17.96, a P/E/G ratio of 0.85 and a beta of 0.52. Pfizer has a twelve month low of $20.92 and a twelve month high of $30.43. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. The stock's fifty day moving average price is $24.37 and its two-hundred day moving average price is $24.53.
Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.21. The company had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The business's revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.60 EPS. On average, research analysts expect that Pfizer will post 2.95 earnings per share for the current fiscal year.
Pfizer Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.9%. The ex-dividend date is Friday, July 25th. Pfizer's dividend payout ratio (DPR) is 124.64%.
Institutional Trading of Pfizer
An institutional investor recently raised its position in Pfizer stock. Brighton Jones LLC grew its position in Pfizer Inc. (NYSE:PFE - Free Report) by 1,282.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 666,318 shares of the biopharmaceutical company's stock after acquiring an additional 618,117 shares during the quarter. Brighton Jones LLC's holdings in Pfizer were worth $17,677,000 as of its most recent SEC filing. Institutional investors own 68.36% of the company's stock.
About Pfizer
(
Get Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
